Steven Safran, MD
Ophthalmology · Lawrenceville, NJNPI 1386624864
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 40.4% of the total. Reporting peaked in 2020 at $12,025 and has fallen 96.0% since, to $476 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $241.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$13K
- Cynosure, LLC$12K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- AbbVie$1K
- Sight Sciences, Inc.$911
- Glaukos Corporation$560
- plus $2K from 14 others
What the payments were for
- Consulting fees$12,53940%
- Speaking & faculty fees$12,00038%
- Food & beverage$6,81022%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 38 | $12,666 |
| Cynosure, LLC | 10 | $11,880 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $2,184 |
| AbbVie(2 entities) | 17 | $1,262 |
| Sight Sciences, Inc. | 19 | $911 |
| Glaukos Corporation | 7 | $560 |
| Bausch & Lomb Americas Inc. | 8 | $482 |
| Carl Zeiss Meditec, Inc. | 5 | $454 |
| Ivantis, Inc | 3 | $227 |
| Rxsight Inc | 3 | $207 |
| Sun Pharmaceutical Industries Inc. | 4 | $173 |
| Alcon | 1 | $95 |
| NEW World Medical,inc. | 1 | $56 |
| Biotissue Holdings Inc. | 2 | $45 |
| Carl Zeiss Meditec USA, Inc. | 1 | $43 |
| Dompe US, Inc. | 1 | $39 |
| Samsara Vision | 1 | $28 |
| Novartis | 2 | $27 |
| Aerie Pharmaceuticals, Inc. | 2 | $27 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$13,287
- Surgitrons$6,115
- Surgitron$5,500
- Tecnis Symfony IOL$3,469
- Healon Viscoelastics$3,344
- Tecnis Multifocal Family of 1-piece IOLS$3,344
- XEN$636
- OMNI(R) SURGICAL SYSTEM (US)$504
- STELLARIS$252
- XEN GLAUCOMA TREATMENT SYSTEM$242
- RXSIGHT CONTACT LENS$156
- RXSIGHT INJECTOR CARTRIDGE$156
- RXSIGHT INJECTOR HANDPIECE$156
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$156
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$156
- LUMIGAN$149
- enVista MX60 IOL$146
- IACCESS$140
- iStent inject W$140
- KXL System$140
How this compares
$31,384 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $79,855 |
| LumiganBimatoprost | 76 | $28,740 |
| Cyclosporine | 44 | $28,245 |
| XiidraLifitegrast | 26 | $20,694 |
| ProlensaBromfenac Sodium | 45 | $16,789 |
| Travoprost | 76 | $13,442 |
| Doxycycline Hyclate | 351 | $11,098 |
| Prednisolone Acetate | 258 | $9,295 |
| Bromfenac Sodium | 49 | $7,696 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $6,780 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 38 | $6,329 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 269 | $5,341 |
| VyzultaLatanoprostene Bunod | 12 | $4,620 |
| Latanoprost | 332 | $3,986 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $3,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,262 | $115,375176 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $482 | $25,31438 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $2,184 | $19,60768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Lawrenceville
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.